S-1/A: OneMedNet Files Amendment to S-1 Registration for Primary and Secondary Offerings

OneMedNet Corporation files an amendment to its S-1 registration statement for a primary offering of common stock upon warrant exercise and a secondary offering of common stock and warrants by selling securityholders.

Summary

• OneMedNet Corporation filed an amendment to its S-1 registration statement.
• The filing covers a primary offering of up to 12,085,275 shares of common stock upon the exercise of warrants.
• It also includes a secondary offering of up to 19,683,367 shares of common stock and up to 681,019 warrants by selling securityholders.
• The primary offering involves shares issuable upon the exercise of public and placement warrants with an exercise price of $11.50 per share.
• The secondary offering includes shares from conversion of convertible notes, warrants, satisfaction agreements, loans, and shares issued to advisors and investors.
• The company will receive proceeds only from the exercise of warrants, while selling securityholders will receive proceeds from their sales.
• The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols ONMD and ONMDW.
• As of April 15, 2024, OneMedNet had approximately 23,850,010 shares of common stock and 12,181,019 warrants outstanding.
• The last reported closing price on April 15, 2024, was $0.68 per share and $0.180 per warrant.
• OneMedNet is classified as an emerging growth company and a smaller reporting company, allowing for certain reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential for growth in the real-world data market and the company's efforts to expand its sales network, the history of operating losses, declining revenue, and potential risks associated with the company's stock price and ability to maintain listing on Nasdaq contribute to a negative sentiment.

Positives

• The company has the potential to receive up to approximately $138.9 million from the exercise of warrants.
• The company is expanding its sales network across the globe, while simultaneously building out its sales infrastructure.
• The company is focused on delivering value by supporting Life Science Advancements with OneMedNets iRWDTM which holds the key to unlocking boundless patient care advances.

Negatives

• The company has a history of operating losses and may never achieve profitability in the future.
• The company's revenue declined in 2023 over 2022.
• The company's stock price may be volatile, and purchasers of our Common Stock could incur substantial losses.
• The company may be unable to execute its business objectives and growth strategies successfully or sustain its growth and, as a result, this could have a material adverse effect on our operating results.

Risks

• The company's stock price may be volatile.
• The company may be unable to maintain listing on Nasdaq.
• The company's principal stockholders will continue to have significant influence.
• The company has broad discretion in the use of the net proceeds from this offering.
• The company could be subject to securities class action litigation.
• The company may be unable to execute its business objectives and growth strategies successfully or sustain its growth and, as a result, this could have a material adverse effect on our operating results.
• The company may be unable to attract and retain key employees and qualified personnel, our ability to compete could be harmed.
• The company may be unable to execute our business objectives and growth strategies successfully or sustain our growth and, as a result, this could have a material adverse effect on our operating results.

Future Outlook

The company's future rate of growth may not be sustainable or indicative of its future rate of growth. The company believes that its continued revenue growth, as well as its ability to reach profitability, will depend upon, among other factors, its ability to address the challenges, risks and difficulties described elsewhere in this proxy statement/prospectus.

Industry Context

The company operates in the real-world data and real-world evidence market, which is projected to grow significantly. The global real world evidence solutions market is projected to grow from $16.13 billion in 2023 to $36.24 billion by 2030, at a CAGR of 12.3%.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards in terms of financial performance or operational metrics.
• The document does not provide specific comparisons to comparible companies in terms of financial performance or operational metrics.
• The document does not provide specific comparisons to comparible projects in terms of financial performance or operational metrics.

Management Changes

Related Party Transactions

• The company received a total of $ 300,000 from members of the Companys Management and Directors.
• In November 2023, the Company entered into a Securities Purchase Agreement (SPA) in which the Company was required to sell senior secured convertible notes and warrants to Directors of the Company.

Stakeholder Impact

• The offering will dilute existing shareholders.
• The company's ability to raise additional capital may be affected by the market price of its securities.
• The company's ability to use net operating loss and tax credit carryforwards may be subject to certain limitations.

Next Steps

• The company intends to file a Registration Statement on Form S-8 registering an aggregate of 360,000 shares of Common Stock underlying equity awards.
• The company is evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Global Market.

Key Dates

Keywords

common stock, warrants, registration statement, offering, OneMedNet, securities, PIPE, securityholders, Data Knights, conversion